- Community-Beiträge
- Aktuellste Threads
Werden Sie mit Ihrer Handelsstrategie der Trader 2026 und gewinnen Sie einen Range Rover Evoque. Hier anmelden!
| Geld/Brief | 1,44 $ / 1,46 $ |
| Spread | +1,39% |
| Schluss Vortag | 1,54 $ |
| Gehandelte Stücke | 290.859 |
| Tagesvolumen Vortag | 281.052,8 $ |
| Tagestief 1,44 $ Tageshoch 1,54 $ | |
| 52W-Tief 1,39 $ 52W-Hoch 3,53 $ | |
| Jahrestief 1,39 $ Jahreshoch 2,48 $ | |
| Umsatz in Mio. | 11,16 $ |
| Operatives Ergebnis (EBIT) in Mio. | -148,68 $ |
| Jahresüberschuss in Mio. | -148,13 $ |
| Umsatz je Aktie | 0,12 $ |
| Gewinn je Aktie | -1,57 $ |
| Gewinnrendite | -1.327,40% |
| Umsatzrendite | -1.327,40% |
| Return on Investment | -84,47% |
| Marktkapitalisierung in Mio. | 168,32 $ |
| KGV (Kurs/Gewinn) | -1,01 |
| KBV (Kurs/Buchwert) | 1,23 |
| KUV (Kurs/Umsatz) | 13,25 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +69,67% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| AMEX | 1,455 $ | -6,73% | 1,56 $ | 09.09.26 | |
| Nasdaq | 1,44 $ | -6,49% | 1,54 $ | 09.09.26 | |
| NYSE | 1,445 $ | -6,77% | 1,55 $ | 09.09.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 09.09.26 | 1,44 | 489 T |
| 08.09.26 | 1,54 | 281 T |
| 04.09.26 | 1,57 | 462 T |
| 03.09.26 | 1,57 | 167 T |
| 02.09.26 | 1,60 | 155 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 1,57 $ | -8,28% |
| 1 Monat | 1,66 $ | -13,25% |
| 6 Monate | 2,03 $ | -29,06% |
| 1 Jahr | 1,78 $ | -19,10% |
| 5 Jahre | 28,85 $ | -95,01% |
| Marktkapitalisierung | 168,32 Mio. $ |
| Streubesitz | 50,74% |
| Währung | USD |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +5,04% | Pfizer Inc |
| +4,39% | Vanguard Group Inc |
| +3,80% | Vanguard Capital Management, LLC |
| +3,29% | Kynam Capital Management, LP |
| +3,04% | Vanguard Morn Total Stk Mkt Idx Investor |
| +2,84% | Vanguard MStar Total Stk Mkt Idx Invest |
| +2,84% | Vanguard Total Stock Mkt Idx Inv |
| +2,44% | Schonfeld Strategic Advisors LLC |
| +2,33% | iShares Russell 2000 ETF |
| +2,15% | ACATIS Datini Valueflex Fonds A |
| +2,02% | BlackRock Inc |
| +1,75% | Renaissance Technologies Corp |
| +1,67% | Millennium Management LLC |
| +1,61% | Selectra J. Lamarck Biotech A |
| +1,55% | Two Sigma Advisers, LLC |
| +1,49% | abrdn Life Sciences Investors |
| +1,46% | Partner Fund Management LP |
| +1,40% | Dimensional Fund Advisors, Inc. |
| +1,35% | Canada Life US Small-Mid Cap Growth F |
| +1,07% | Susquehanna International Group, LLP |
| +1,05% | Geode Capital Management, LLC |
| +1,03% | Jacobs Levy Equity Management, Inc. |
| +1,00% | Two Sigma Investments LLC |
| +0,96% | Aberdeen Group PLC |
| +0,95% | Mackenzie Investments |
| +0,95% | Vanguard Institutional Extnd Mkt Idx Tr |
| +0,93% | Fidelity Small Cap Index |
| +0,93% | Acadian Asset Management LLC |
| +0,91% | Marshall Wace Asset Management Ltd |
| +0,88% | iShares Russell 2000 Value ETF |
| +0,87% | Bank of America Corp |
| +0,85% | Goldman Sachs Group Inc |
| +0,83% | Pale Fire Capital SE |
| +0,78% | FMR Inc |
| +0,70% | Maverick Capital Ltd |
| +0,69% | AQR Capital Management LLC |
| +0,65% | iShares Biotechnology ETF |
| +0,64% | Royal Bank of Canada |
| +0,62% | CAMBRIDGE Invest RESEARCH ADVISORS, INC. |
| +0,60% | Russell 2000 Index Non-Lendable Fund |
| +0,60% | Russell 2000 Equity Index Fund B |
| +0,59% | Charles Schwab Investment Management Inc |
| +0,53% | Vanguard Russell 2000 ETF |
| +0,52% | Vanguard Fiduciary Trust Co |
| +0,52% | Fidelity Extended Market Index |
| +0,50% | State St Russell Sm/Mid Cp® Indx SL Cl I |
| +0,50% | Jane Street Group LLC |
| +0,47% | Mackenzie Quantitative US Small Cap |
| +0,45% | 72 Investment Holdings, LLC |
| +0,44% | GSA Capital Partners LLP |
| +0,43% | Schwab US Small-Cap ETF™ |
| +0,42% | DFA US Targeted Value I |
| +0,34% | State St Russell Sm Cap® Idx SL Cl I |
| +0,33% | Dimensional US Targeted Value ETF |
| +0,31% | Fidelity Enhanced Small Cap Core ETF |
| +0,31% | iShares Micro-Cap ETF |
| +0,28% | Mackenzie GQE US Small Cap F8 |
| +0,27% | Bruce |
| +0,25% | DFA US Small Cap I |
| +0,23% | AXS Green Alpha ETF |
| +0,22% | Dimensional US Small Cap ETF |
| +0,22% | Blackrock Extended Mkt Fund CF |
| +0,21% | NT R2000 Index Fund - NL |
| +0,21% | Extended Equity Market Fund E |
| +0,21% | Extended Equity Market Fund B |
| +0,21% | Goldman Sachs Small Cp Val Insghts Instl |
| +0,19% | Extended Equity Market Fund K |
| +0,18% | BlackRock Extended Equity Market Fund K |
| +0,16% | Fidelity Total Market Index |
| +0,14% | Multi-Manager Small Cap Eq Strat Inst |
| +0,14% | Bridgeway Ultra-Small Company Market |
| +0,14% | Galileo - Biotech Innovation Fund S USD |
| +0,13% | Fidelity Series Total Market Index |
| +0,12% | Avantis US Small Cap Equity ETF |
| +0,12% | Dimensional US Core Equity 2 ETF |
| +0,11% | BlackRock Global Equity Mkt Netrl Instl |
| +0,11% | NT Ext Equity Mkt Idx Fd - L |
| +0,11% | Spartan Extended Market Index Pool F |
| +0,1% | Northern Trust Extended Eq Market Idx |
| +39,548% | Institutionelle Aktionäre |
| +9,715% | Insider Aktionäre |
| +50,737% | Streubesitz |
Pipeline Update
https://finance.yahoo.com/news/caribou-cuts-pipeline-workforce-focus-115051904.html
249 Mio. $. Cash sollen bis H2/26 reichen. Die aktuelle MK liegt bei 96 Mio. $. Die nächsten Katalysatoren werden noch in diesem Halbjahr erwartet:
- CB-010 ANTLER 2L LBCL und
- CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025
Zahlen für Q3/24
- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025
-- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025
-- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation data to be presented H1 2025
